一氧化氮供体型比马前列素NCX 470与拉坦前列素在开角型青光眼或高眼压受试者中的随机对照比较:MONT BLANC研究
这项前瞻性3期随机双盲平行组试验纳入691例开角型青光眼或高眼压受试者,比较NCX 470 0.065%、NCX 470 0.1%与拉坦前列素0.005%的降眼压疗效与安全性。共661例纳入分析,NCX 470 0.1%组各治疗时点眼压均显著降低,降幅8.0至9.7 mmHg(各时点P < .0001),6个时点平均眼压降幅均大于拉坦前列素0.005%,其中4个时点差异显著(P < .05)。最常见不良事件为结膜/眼部充血。
要点
- NCX 470 0.1%组各治疗时点眼压均显著降低,降幅8.0至9.7 mmHg(各时点P < .0001)。
- NCX 470 0.1%在全部6个时点平均眼压降幅均大于拉坦前列素0.005%,其中4个时点差异显著(P < .05)。
- 最常见不良事件为结膜/眼部充血。
核心结论
- 一氧化氮供体型前列腺素类似物NCX 470 0.1%耐受性良好,在全部6个时点降眼压幅度均大于拉坦前列素。
- 作者认为,NCX 470通过同时增强葡萄膜巩膜和小梁网流出途径的双重作用机制,可能成为青光眼降眼压的重要一线治疗。
研究设计与样本
- 前瞻性、3期、随机、适应性剂量选择、双盲、平行组试验。
- 纳入691例开角型青光眼或高眼压受试者,研究眼未用药眼压满足8AM ≥26 mmHg、10AM ≥24 mmHg、4PM ≥22 mmHg。
- 受试者随机分配至NCX 470 0.065%、NCX 470 0.1%或拉坦前列素0.005%组。
- 通过期中分析选择NCX 470的最终剂量。
- 基于2周、6周和3个月时8AM与4PM相对基线的眼压降幅评估NCX 470对拉坦前列素的非劣效性。
主要发现
- 共661例受试者纳入分析。
- NCX 470 0.1%组各治疗时点眼压均显著降低,降幅范围为8.0至9.7 mmHg(各时点P < .0001)。
- NCX 470 0.1%组在全部6个时点的平均眼压降幅均大于拉坦前列素0.005%组,其中4个时点差异显著(P < .05)。
- 最常见不良事件为结膜/眼部充血。
临床怎么用
- 原文结论认为NCX 470 0.1%耐受性良好且降眼压幅度大于拉坦前列素,作者认为其可能成为青光眼降眼压的重要一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). DESIGN: Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial. METHODS: 691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months. RESULTS: 661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia. CONCLUSION: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.
引用
- Fechtner R, Mansberger S, Branch J, et al. A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study. Am J Ophthalmol. 2024. PMID: 38499140. doi:10.1016/j.ajo.2024.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。